The stock of Amicus Therapeutics Inc. (NASDAQ:FOLD) decreased by -$0.3 on Tuesday to finish at $12.99, down -2.26 percent. The last five days have seen an average of 2,356,520 shares of common stock traded. 8 times new highs were reached in the current year, with a gain of $0.78. The average number of shares traded over the last 20 days was 2,997,270, while the average volume over the last 50 days totaled 2,589,382.
FOLD stock dropped -2.70% since last month. On 08/08/23, the company’s shares reached a one-month low of $12.22. The stock touched a high of $14.10 on 08/09/23, after rallying from a low of $9.10 in 52 weeks. The price of FOLD stock has risen by 6.39% or $0.78 this year, reaching a new high 8 times. Still, the stock price is down -7.87% from the 52-week high.
Insider Transactions
FOLD stock investors should be aware that Amicus Therapeutics Inc. (FOLD) stock had its last reported insider trading activity 7 days ago on Aug 09. On Aug 09, Chief Accounting Officer Prout Samantha sold 36,909 shares at $14.01 each. This transaction resulted in the insider making $516,933. On Aug 01, Campbell Bradley L sold 20,000 shares at a price of US$13.39. After the transaction, the insider now owns 798,554 shares. Executive Chairman Crowley John F had earlier sold 6,044 shares on Aug 01 for $13.35 a share. The transaction was completed for $80,716.
Valuation Metrics
Beta for the stock is 0.85. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 10.53, the price-to-book (PB) ratio of 34.18.
Financial Health
For the three months ended June 29, Amicus Therapeutics Inc.’s quick ratio was 2.40, while its current ratio was 2.70, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 3.53, and the total debt to equity ratio is 3.53. As far as profitability goes, gross margin for the trailing twelve months is 88.90% percent. Amicus Therapeutics Inc.’s EBITDA margin for the year ended June 29 was -60.47%, whereas its operating margin stood at -37.80% for the same period. Based on annual data, it had gross profit of $290.63 million and revenue of $329.23 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. FOLD’s return on assets (ROA) during the last 12 months has been -25.40%. There was a -40.10% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -157.80%.
Earnings Surprise
According to Amicus Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29, it had $393.35 million in total debt versus $54.32 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $94.39 million, while revenues rose by 14.47% to $86.27 million. It was predicted that Amicus Therapeutics Inc.’s quarterly earnings would be -$0.15, but it ended up being -$0.12, beating the consensus by -25.00%. EBITDA was -$15.96 million for the quarter. At the end of Amicus Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 618.51 million, while its total debt was $452.17 million. Equity owned by shareholders amounts to $287.12 million.
Technical Picture
Here’s a quick look at Amicus Therapeutics Inc.’s (FOLD) price momentum from a technical perspective. As of 15 August, the RSI 9-day stood at 43.81%, suggesting the stock is Neutral, with a 63.18% historical volatility rate.
The stochastic %K and %D were 53.90% and 59.66% respectively, while the average true range (ATR) was 0.50. Based on the 14-day stochastic reading of 40.96%, the RSI (14) reading is 47.32%. On the 9-day MACD Oscillator, the stock is at -0.06, and the 14-day reading is at -0.12.
Analyst Ratings
In its analyst report released on September 09, 2022, Morgan Stanley began covering Amicus Therapeutics Inc. (NASDAQ: FOLD). The stock was rated as an Equal-weight by the brokerage firm. Analysts have assigned Amicus Therapeutics Inc. (FOLD) an Overweight rating. FOLD is a stock that is recommended for selling by 0 brokerage firms, while 5 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 7 others recommend it as a buy.
What is FOLD’s price target for the next 12 months?
The current consensus forecast for the stock is between $12.00 and $20.00, with a median target price of $16.00. In analyzing these forecasts, the average price target given by analysts for Amicus Therapeutics Inc. (FOLD) is $16.30.
